Cost-of-illness Analysis and Regression Modeling in Cystic Fibrosis: a Retrospective Prevalence-based Study

Overview

Journal Eur J Health Econ

Specialty Health Services

Date 2016 Jan 9

PMID 26743971

Citations 5

Authors

Tomas Mlcoch

Jiri Klimes

Libor Fila

Vera Vavrova

Veronika Skalicka

Marek Turnovec

Veronika Krulisova

Jitka Jircikova

Dana Zemkova

Klara Vilimovska Dedeckova

Alena Bilkova

Vladimira Fruhaufova

Lukas Homola

Zuzana Friedmannova

Radovan Drnek

Pavel Drevinek

Tomas Dolezal

Milan Macek Jr

Affiliations

Soon will be listed here.

Abstract

Background: Economic data pertaining to cystic fibrosis (CF), is limited in Europe generally, and completely lacking in Central and Eastern Europe. We performed an analysis of all direct costs associated with CF relative to key disease features and laboratory examinations.

Methods: A retrospective prevalence-based cost-of-illness (COI) study was performed in a representative cohort of 242 CF patients in the Czech Republic, which represents about 65 % of all Czech CF patients. Medical records and invoices to health insurance companies for reference year 2010 were analyzed.

Results: The mean total health care costs were €14,486 per patient, with the majority of the costs going towards medicinal products and devices (€10,321). Medical procedures (€2676) and inpatient care (€1829) represented a much smaller percentage of costs. A generalized linear model showed that the strongest cost drivers, for all cost categories, were associated with patient age and lung disease severity (assessed using the FEV1 spirometric parameter), when compounded by chronic Pseudomonas aeruginosa airway infections. Specifically, maximum total costs are around the age 16 years; a FEV1 increase of 1 % point represented a cost decrease of: 0.9 % (medicinal products), 1.7 % (total costs), 2.8 % (procedures) and 7.0 % (inpatient care).

Conclusions: COI analysis and regression modeling using the most recent data available can provide a better understanding of the overall economic CF burden. A comparison of our results with other methodologically similar studies demonstrates that although overall costs may differ, FEV1 can nonetheless be utilized as a generally transferrable indicator of the relative economic impact of CF.

Citing Articles

Factors associated with frequent high-cost individuals with cystic fibrosis and their healthcare utilization and cost patterns.

Desai S, Zhang W, Sutherland J, Singer J, Quon B Sci Rep. 2023; 13(1):8910.

PMID: 37264136 PMC: 10235057. DOI: 10.1038/s41598-023-35942-7.

Cost-of-illness studies in rare diseases: a scoping review.

Garcia-Perez L, Linertova R, Valcarcel-Nazco C, Posada M, Gorostiza I, Serrano-Aguilar P Orphanet J Rare Dis. 2021; 16(1):178.

PMID: 33849613 PMC: 8045199. DOI: 10.1186/s13023-021-01815-3.

Cost-of-illness studies in nine Central and Eastern European countries.

Brodszky V, Beretzky Z, Baji P, Rencz F, Pentek M, Rotar A Eur J Health Econ. 2019; 20(Suppl 1):155-172.

PMID: 31104219 PMC: 6544593. DOI: 10.1007/s10198-019-01066-x.

Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis.

Mlcoch T, Tuzil J, Sedova L, Stolfa J, Urbanova M, Suchy D Patient. 2017; 11(3):329-340.

PMID: 29164493 DOI: 10.1007/s40271-017-0285-1.

Dietary patterns, cost and compliance with low-protein diet of phenylketonuria and other inherited metabolic diseases.

Mlcoch T, Puda R, Jesina P, Lhotakova M, Sterbova S, Dolezal T Eur J Clin Nutr. 2017; 72(1):87-92.

PMID: 28656971 DOI: 10.1038/ejcn.2017.102.

References

Reid D, Blizzard C, Shugg D, Flowers C, Cash C, Greville H . Changes in cystic fibrosis mortality in Australia, 1979-2005. Med J Aust. 2011; 195(7):392-5. DOI: 10.5694/mja10.11229. View

Goss C, Ratjen F . Update in cystic fibrosis 2012. Am J Respir Crit Care Med. 2013; 187(9):915-9. PMC: 5448509. DOI: 10.1164/rccm.201301-0184UP. View

Heimeshoff M, Hollmeyer H, Schreyogg J, Tiemann O, Staab D . Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre. Pharmacoeconomics. 2012; 30(9):763-77. DOI: 10.2165/11588870-000000000-00000. View

Marchetti F, Giglio L, Candusso M, Faraguna D, Assael B . Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature. Eur J Clin Pharmacol. 2004; 60(2):67-74. DOI: 10.1007/s00228-004-0735-2. View

Mehta G, Macek Jr M, Mehta A . Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries. J Cyst Fibros. 2010; 9 Suppl 2:S5-S21. DOI: 10.1016/j.jcf.2010.08.002. View

Snell C, Fernandes S, Bujoreanu I, Garcia G . Depression, illness severity, and healthcare utilization in cystic fibrosis. Pediatr Pulmonol. 2014; 49(12):1177-81. DOI: 10.1002/ppul.22990. View

Gu Y, Garcia-Perez S, Massie J, van Gool K . Cost of care for cystic fibrosis: an investigation of cost determinants using national registry data. Eur J Health Econ. 2014; 16(7):709-17. DOI: 10.1007/s10198-014-0621-5. View

Kerem E, Conway S, Elborn S, Heijerman H . Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2005; 4(1):7-26. DOI: 10.1016/j.jcf.2004.12.002. View

Lomas P . Enhancing adherence to inhaled therapies in cystic fibrosis. Ther Adv Respir Dis. 2014; 8(2):39-47. DOI: 10.1177/1753465814524471. View

10.

Krenkova P, Piskackova T, Holubova A, Balascakova M, Krulisova V, camajova J . Distribution of CFTR mutations in the Czech population: positive impact of integrated clinical and laboratory expertise, detection of novel/de novo alleles and relevance for related/derived populations. J Cyst Fibros. 2013; 12(5):532-7. DOI: 10.1016/j.jcf.2012.12.002. View

11.

Miller M, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A . Standardisation of spirometry. Eur Respir J. 2005; 26(2):319-38. DOI: 10.1183/09031936.05.00034805. View

12.

Vasiliadis H, Collet J, Penrod J, Ferraro P, Poirier C . A cost-effectiveness and cost-utility study of lung transplantation. J Heart Lung Transplant. 2005; 24(9):1275-83. DOI: 10.1016/j.healun.2004.10.012. View

13.

Farrell P, Rosenstein B, White T, Accurso F, Castellani C, Cutting G . Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008; 153(2):S4-S14. PMC: 2810958. DOI: 10.1016/j.jpeds.2008.05.005. View

14.

Yankaskas J, Marshall B, Sufian B, Simon R, Rodman D . Cystic fibrosis adult care: consensus conference report. Chest. 2004; 125(1 Suppl):1S-39S. DOI: 10.1378/chest.125.1_suppl.1s. View

15.

Larg A, Moss J . Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011; 29(8):653-71. DOI: 10.2165/11588380-000000000-00000. View

16.

Colombo C, Dacco V, Alicandro G, Loi S, Mazzi S, Lucioni C . Cost of cystic fibrosis: analysis of treatment costs in a specialized center in northern Italy. Adv Ther. 2013; 30(2):165-75. DOI: 10.1007/s12325-013-0008-5. View

17.

Chevreul K, Brigham K, Michel M, Rault G . Costs and health-related quality of life of patients with cystic fibrosis and their carers in France. J Cyst Fibros. 2015; 14(3):384-91. DOI: 10.1016/j.jcf.2014.11.006. View

18.

De Boeck K, Zolin A, Cuppens H, Olesen H, Viviani L . The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. J Cyst Fibros. 2014; 13(4):403-9. DOI: 10.1016/j.jcf.2013.12.003. View

19.

McCormick J, Mehta G, Olesen H, Viviani L, Macek Jr M, Mehta A . Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. Lancet. 2010; 375(9719):1007-13. DOI: 10.1016/S0140-6736(09)62161-9. View

20.

Balascakova M, Holubova A, Skalicka V, Zemkova D, Kracmar P, Gonsorcikova L . Pilot newborn screening project for cystic fibrosis in the Czech Republic: defining role of the delay in its symptomatic diagnosis and influence of ultrasound-based prenatal diagnosis on the incidence of the disease. J Cyst Fibros. 2009; 8(3):224-7. DOI: 10.1016/j.jcf.2009.01.002. View